Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEACON CRC phase 3 trial of encorafenib + cetuximab with or without binimetinib in BRAF V600E metastatic colorectal cancer
NL-OMON47693Phase 3Completed
- Sponsor
- Array BioPharma
- Start
- Oct 2016
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of encorafenib, binimetinib, cetuximab, irinotecan, fluorouracil and 1 more in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) (4 arms), sponsored by Array BioPharma. Primary endpoints: Dose-limiting toxicities, Safety and tolerability and 1 more. Started Oct 2016; status: completed.
02
Drugs
encorafenibbinimetinibcetuximabirinotecanfluorouracil
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on NL-OMON47693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47693.